{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:47:56Z","timestamp":1787003276336,"version":"build-2736575974"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41579-020-00441-3","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T06:05:20Z","timestamp":1599717920000},"page":"690-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4542-7684","authenticated-orcid":false,"given":"Emmanuel","family":"Margolin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Sturrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-3893","authenticated-orcid":false,"given":"Marc","family":"Mendelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-2099","authenticated-orcid":false,"given":"Rosamund","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8929-6279","authenticated-orcid":false,"given":"Nicola","family":"Douglass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lise","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"441_CR1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","volume":"24","author":"S Su","year":"2016","unstructured":"Su, S. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24, 490\u2013502 (2016).","journal-title":"Trends Microbiol."},{"key":"441_CR2","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"C Drosten","year":"2003","unstructured":"Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967\u20131976 (2003).","journal-title":"N. Engl. J. Med."},{"key":"441_CR3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814\u20131820 (2012).","journal-title":"N. Engl. J. Med."},{"key":"441_CR4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"441_CR5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507\u2013513 (2020).","journal-title":"Lancet"},{"key":"441_CR6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533\u2013534 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"441_CR7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"441_CR8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.cub.2020.03.022","volume":"30","author":"T Zhang","year":"2020","unstructured":"Zhang, T., Wu, Q. & Zhang, Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr. Biol. 30, 1346\u20131351 (2020).","journal-title":"Curr. Biol."},{"key":"441_CR9","doi-asserted-by":"crossref","first-page":"eabb9153","DOI":"10.1126\/sciadv.abb9153","volume":"6","author":"X Li","year":"2020","unstructured":"Li, X. et al. Emergence of SARS-CoV-2 through recombination and strong purifying selection. Sci. Adv. 6, eabb9153 (2020).","journal-title":"Sci. Adv."},{"key":"441_CR10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475\u2013481 (2020).","journal-title":"Lancet Respir. Med."},{"key":"441_CR11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"441_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14057","author":"J Li","year":"2020","unstructured":"Li, J. et al. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes. Metab. https:\/\/doi.org\/10.1111\/dom.14057 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"441_CR13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa360","author":"NE Palermo","year":"2020","unstructured":"Palermo, N. E., Sadhu, A. R. & McDonnell, M. E. Diabetic ketoacidosis in COVID-19: unique concerns and considerations. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa360 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"441_CR14","unstructured":"International Diabetes Foundation. IDF Africa. IDF https:\/\/idf.org\/our-network\/regions-members\/africa\/welcome.html (2019)."},{"key":"441_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30287-X","author":"A Varatharaj","year":"2020","unstructured":"Varatharaj, A. et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiat. https:\/\/doi.org\/10.1016\/S2215-0366(20)30287-X (2020).","journal-title":"Lancet Psychiat."},{"key":"441_CR16","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(20)31094-1","volume":"395","author":"S Riphagen","year":"2020","unstructured":"Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N. & Theocharis, P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395, 1607\u20131608 (2020).","journal-title":"Lancet"},{"key":"441_CR17","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(20)31129-6","volume":"395","author":"RM Viner","year":"2020","unstructured":"Viner, R. M. & Whittaker, E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet 395, 1741\u20131743 (2020).","journal-title":"Lancet"},{"key":"441_CR18","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMc2005073","volume":"382","author":"X Lu","year":"2020","unstructured":"Lu, X. et al. SARS-CoV-2 infection in children. N. Engl. J. Med. 382, 1663\u20131665 (2020).","journal-title":"N. Engl. J. Med."},{"key":"441_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba9757","author":"M Chinazzi","year":"2020","unstructured":"Chinazzi, M. et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science https:\/\/doi.org\/10.1126\/science.aba9757 (2020).","journal-title":"Science"},{"key":"441_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30464-5","author":"JN Nkengasong","year":"2020","unstructured":"Nkengasong, J. N. & Mankoula, W. Looming threat of COVID-19 infection in Africa: act collectively, and fast. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(20)30464-5 (2020).","journal-title":"Lancet"},{"key":"441_CR21","unstructured":"World Health Organization. Hospital beds (per 10 000 population). WHO https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/hospital-beds-(per-10-000-population) (2020)."},{"key":"441_CR22","doi-asserted-by":"crossref","first-page":"m1637","DOI":"10.1136\/bmj.m1637","volume":"369","author":"J Thornton","year":"2020","unstructured":"Thornton, J. Covid-19: keep essential malaria services going during pandemic, urges WHO. BMJ 369, m1637 (2020).","journal-title":"BMJ"},{"key":"441_CR23","unstructured":"Basson, A. Zimbabwe under strain as Malaria cases surge during COVID-19 fight. news24 https:\/\/www.news24.com\/Africa\/News\/zimbabwe-under-strain-as-malaria-cases-surge-during-covid-19-fight-20200424 (2020)."},{"key":"441_CR24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1126\/science.abb3221","volume":"368","author":"R Li","year":"2020","unstructured":"Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science 368, 489-493 (2020).","journal-title":"Science"},{"key":"441_CR25","unstructured":"Our World in Data. Coronavirus (COVID-19) testing. Global Change Data Lab https:\/\/ourworldindata.org\/coronavirus-testing#how-many-tests-are-performed-each-day (2020)."},{"key":"441_CR26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0140-6736(20)30690-5","volume":"395","author":"A Saglietto","year":"2020","unstructured":"Saglietto, A., D\u2019Ascenzo, F., Zoccai, G. B. & De Ferrari, G. M. COVID-19 in Europe: the Italian lesson. Lancet 395, 1110\u20131111 (2020).","journal-title":"Lancet"},{"key":"441_CR27","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1016\/S2214-109X(20)30074-7","volume":"8","author":"J Hellewell","year":"2020","unstructured":"Hellewell, J. et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob. Health 8, e488\u2013e496 (2020).","journal-title":"Lancet Glob. Health"},{"key":"441_CR28","first-page":"429","volume":"110","author":"M Mendelson","year":"2020","unstructured":"Mendelson, M. & Madhi, S. South Africa\u2019s coronavirus testing strategy is broken and not fit for purpose: it\u2019s time for a change. SAMJ 110, 429\u2013431 (2020).","journal-title":"SAMJ"},{"key":"441_CR29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/d41586-020-01265-0","volume":"580","author":"J Nkengasong","year":"2020","unstructured":"Nkengasong, J. Let Africa into the market for COVID-19 diagnostics. Nature 580, 565 (2020).","journal-title":"Nature"},{"key":"441_CR30","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","author":"VM Corman","year":"2020","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.3.2000045 (2020).","journal-title":"Euro Surveill."},{"key":"441_CR31","unstructured":"The Guardian (international edition). African countries unite to create \u2018one stop shop\u2019 to lower cost of Covid-19 tests and PPE. The Guardian https:\/\/www.theguardian.com\/global-development\/2020\/jun\/22\/the-power-of-volume-africa-unites-to-lower-cost-of-covid-19-tests-and-ppe (2020)."},{"key":"441_CR32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7196\/SAMJ.2020.v110i8.15055","volume":"110","author":"SA Madhi","year":"2020","unstructured":"Madhi, S. A. et al. COVID-19 lockdowns in low- and middle-income countries: success against COVID-19 at the price of greater costs. SAMJ 110, 724\u2013726 (2020).","journal-title":"SAMJ"},{"key":"441_CR33","doi-asserted-by":"crossref","first-page":"2000398","DOI":"10.2807\/1560-7917.ES.2020.25.14.2000398","volume":"25","author":"AS Fomsgaard","year":"2020","unstructured":"Fomsgaard, A. S. & Rosenstierne, M. W. An alternative workflow for molecular detection of SARS-CoV-2 \u2013 escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020. Eurosurveillance 25, 2000398 (2020).","journal-title":"Eurosurveillance"},{"key":"441_CR34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41587-020-0513-4","volume":"38","author":"JP Broughton","year":"2020","unstructured":"Broughton, J. P. et al. CRISPR\u2013Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 38, 870\u2013874 (2020).","journal-title":"Nat. Biotechnol."},{"key":"441_CR35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020).","journal-title":"Nat. Med."},{"key":"441_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013652","author":"JJ Deeks","year":"2020","unstructured":"Deeks, J. J. et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD013652 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"441_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.07.20124636","author":"HM Staines","year":"2020","unstructured":"Staines, H. M. et al. Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.06.07.20124636 (2020).","journal-title":"medRxiv"},{"key":"441_CR38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2025179","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo, F. J. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2025179 (2020).","journal-title":"N. Engl. J. Med."},{"key":"441_CR39","doi-asserted-by":"crossref","DOI":"10.1002\/cpmc.100","volume":"57","author":"D Stadlbauer","year":"2020","unstructured":"Stadlbauer, D. et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57, e100 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"441_CR40","doi-asserted-by":"publisher","DOI":"10.3201\/eid2607.200841","author":"NMA Okba","year":"2020","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg. Infect. Dis. https:\/\/doi.org\/10.3201\/eid2607.200841 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"441_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.09.20056325","author":"R Lassauni\u00e8re","year":"2020","unstructured":"Lassauni\u00e8re, R. et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.04.09.20056325 (2020).","journal-title":"medRxiv"},{"key":"441_CR42","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(20)30788-1","volume":"395","author":"A Petherick","year":"2020","unstructured":"Petherick, A. Developing antibody tests for SARS-CoV-2. Lancet 395, 1101\u20131102 (2020).","journal-title":"Lancet"},{"key":"441_CR43","doi-asserted-by":"crossref","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","volume":"5","author":"L Premkumar","year":"2020","unstructured":"Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020).","journal-title":"Sci. Immunol."},{"key":"441_CR44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jviromet.2016.07.025","volume":"236","author":"R Atkinson","year":"2016","unstructured":"Atkinson, R., Burt, F., Rybicki, E. P. & Meyers, A. E. Plant-produced Crimean\u2013Congo haemorrhagic fever virus nucleoprotein for use in indirect ELISA. J. Virol. Methods 236, 170\u2013177 (2016).","journal-title":"J. Virol. Methods"},{"key":"441_CR45","doi-asserted-by":"crossref","DOI":"10.1186\/s12896-018-0489-z","volume":"18","author":"S Mbewana","year":"2018","unstructured":"Mbewana, S. et al. Expression of Rift Valley fever virus N-protein in Nicotiana benthamiana for use as a diagnostic antigen. BMC Biotechnol. 18, 77 (2018).","journal-title":"BMC Biotechnol."},{"key":"441_CR46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jviromet.2004.08.015","volume":"122","author":"X Han","year":"2004","unstructured":"Han, X. et al. The expression of SARS-CoV M gene in P. Pastoris and the diagnostic utility of the expression product. J. Virol. Methods 122, 105\u2013111 (2004).","journal-title":"J. Virol. Methods"},{"key":"441_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/pbi.13369","author":"E Margolin","year":"2020","unstructured":"Margolin, E. et al. Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants. Plant Biotechnol. J. https:\/\/doi.org\/10.1111\/pbi.13369 (2020).","journal-title":"Plant Biotechnol. J."},{"key":"441_CR48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat, F. & Krammer, F. SARS-CoV-2 vaccines: status report. Immunity 52, 583\u2013589 (2020).","journal-title":"Immunity"},{"key":"441_CR49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"441_CR50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of COVID-19 \u2014 preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N. Engl. J. Med."},{"key":"441_CR51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"RC Group","year":"2020","unstructured":"Group, R. C. et al. Dexamethasone in hospitalized patients with COVID-19 \u2013 preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2021436 (2020).","journal-title":"N. Engl. J. Med."},{"key":"441_CR52","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 56, 105949 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"441_CR53","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0140-6736(20)31324-6","volume":"395","author":"MR Mehra","year":"2020","unstructured":"Mehra, M. R., Ruschitzka, F. & Patel, A. N. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 395, 1820 (2020).","journal-title":"Lancet"},{"key":"441_CR54","unstructured":"University of Oxford. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Nuffield Department of Population Health https:\/\/www.recoverytrial.net\/news\/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19 (2020)."},{"key":"441_CR55","unstructured":"World Health Organization. \u201cSolidarity\u201d clinical trial for COVID-19 treatments. WHO https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments (2020)."},{"key":"441_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2558-4","author":"P Maisonnasse","year":"2020","unstructured":"Maisonnasse, P. et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature https:\/\/doi.org\/10.1038\/s41586-020-2558-4 (2020).","journal-title":"Nature"},{"key":"441_CR57","unstructured":"World Health Organization Guidance for Managing Ethical Issues in Infectious Disease Outbreaks (WHO Press, 2016)."},{"key":"441_CR58","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","volume":"367","author":"K Kupferschmidt","year":"2020","unstructured":"Kupferschmidt, K. & Cohen, J. Race to find COVID-19 treatments accelerates. Science 367, 1412\u20131413 (2020).","journal-title":"Science"},{"key":"441_CR59","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA 117, 9490\u20139496 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"441_CR60","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138745","author":"EM Bloch","year":"2020","unstructured":"Bloch, E. M. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI138745 (2020).","journal-title":"J. Clin. Invest."},{"key":"441_CR61","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.30.20047365","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.03.30.20047365 (2020).","journal-title":"medRxiv"},{"key":"441_CR62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"441_CR63","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA 117, 10970\u201310975 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"441_CR64","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing, J. et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis. 20, 400\u2013402 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"441_CR65","unstructured":"Genetic Engineering & Biotechnology News. Phase III trial to study combination of Genentech\u2019s actemra, Gilead\u2019s remdesivir versus severe COVID-19. Genetic Engineering & Biotechnology News https:\/\/www.genengnews.com\/news\/phase-iii-trial-to-study-combination-of-genentechs-actemra-gileads-remdesivir-vs-severe-covid-19\/ (2020)."},{"key":"441_CR66","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","volume":"8","author":"PM George","year":"2020","unstructured":"George, P. M., Wells, A. U. & Jenkins, R. G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir. Med. 8, 807\u2013815 (2020).","journal-title":"Lancet Respir. Med."},{"key":"441_CR67","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"441_CR68","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6750-12-14","volume":"12","author":"E Mortimer","year":"2012","unstructured":"Mortimer, E. et al. Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC Biotechnol. 12, 14 (2012).","journal-title":"BMC Biotechnol."},{"key":"441_CR69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"Le,T Thanh","year":"2020","unstructured":"Thanh Le, T. et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 305\u2013306 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"441_CR70","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(20)31252-6","volume":"395","author":"A Mullard","year":"2020","unstructured":"Mullard, A. COVID-19 vaccine development pipeline gears up. Lancet 395, 1751\u20131752 (2020).","journal-title":"Lancet"},{"key":"441_CR71","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020).","journal-title":"Lancet"},{"key":"441_CR72","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1128\/CVI.00717-15","volume":"23","author":"GE Gray","year":"2016","unstructured":"Gray, G. E. et al. Subtype C gp140 vaccine boosts immune responses primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV vaccines after more than a 2-year gap. Clin. Vaccine Immunol. 23, 496\u2013506 (2016).","journal-title":"Clin. Vaccine Immunol."},{"key":"441_CR73","doi-asserted-by":"crossref","unstructured":"Roussi, A. & Maxmen, A. African nations missing from coronavirus trials. Nature https:\/\/www.nature.com\/articles\/d41586-020-01010-7 (2020).","DOI":"10.1038\/d41586-020-01010-7"},{"key":"441_CR74","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jama.2018.0345","volume":"319","author":"BS Graham","year":"2018","unstructured":"Graham, B. S., Mascola, J. R. & Fauci, A. S. Novel vaccine technologies: essential components of an adequate response to emerging viral diseases. JAMA 319, 1431\u20131432 (2018).","journal-title":"JAMA"},{"key":"441_CR75","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","volume":"9","author":"S Rauch","year":"2018","unstructured":"Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. Front. Immunol. 9, 1963 (2018).","journal-title":"Front. Immunol."},{"key":"441_CR76","volume":"11","author":"TRF Smith","year":"2020","unstructured":"Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).","journal-title":"Nat. Commun."},{"key":"441_CR77","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"441_CR78","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","volume":"7","author":"L Sanchez-Sampedro","year":"2015","unstructured":"Sanchez-Sampedro, L. et al. The evolution of poxvirus vaccines. Viruses 7, 1726\u20131803 (2015).","journal-title":"Viruses"},{"key":"441_CR79","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","volume":"13","author":"K Ewer","year":"2017","unstructured":"Ewer, K. et al. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum. Vaccin. Immunother. 13, 3020\u20133032 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"441_CR80","doi-asserted-by":"crossref","first-page":"eaba8399","DOI":"10.1126\/sciadv.aba8399","volume":"6","author":"N Doremalen","year":"2020","unstructured":"Doremalen, N. versus et al. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci. Adv. 6, eaba8399 (2020).","journal-title":"Sci. Adv."},{"key":"441_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature https:\/\/doi.org\/10.1038\/s41586-020-2608-y (2020).","journal-title":"Nature"},{"key":"441_CR82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/02648725.2018.1471643","volume":"34","author":"LP Nagata","year":"2018","unstructured":"Nagata, L. P., Irwin, C. R., Hu, W. & Evans, D. H. Vaccinia-based vaccines to biothreat and emerging viruses. Biotechnol. Genet. Eng. Rev. 34, 107\u2013121 (2018).","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"441_CR83","first-page":"375","volume":"167","author":"A Mayr","year":"1978","unstructured":"Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl.)]. Zentralbl Bakteriol. B 167, 375\u2013390 (1978).","journal-title":"Zentralbl Bakteriol. B"},{"key":"441_CR84","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/156652308784049363","volume":"8","author":"CE Gomez","year":"2008","unstructured":"Gomez, C. E., Najera, J. L., Krupa, M. & Esteban, M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8, 97\u2013120 (2008).","journal-title":"Curr. Gene Ther."},{"key":"441_CR85","first-page":"131","volume":"82","author":"J Taylor","year":"1994","unstructured":"Taylor, J. et al. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev. Biol. Stand. 82, 131\u2013135 (1994).","journal-title":"Dev. Biol. Stand."},{"key":"441_CR86","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/14760584.4.1.63","volume":"4","author":"MA Skinner","year":"2005","unstructured":"Skinner, M. A., Laidlaw, S. M., Eldaghayes, I., Kaiser, P. & Cottingham, M. G. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev. Vaccines 4, 63\u201376 (2005).","journal-title":"Expert Rev. Vaccines"},{"key":"441_CR87","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/S0264-410X(02)00203-7","volume":"20","author":"K Aspden","year":"2002","unstructured":"Aspden, K. et al. Immunogenicity of a recombinant lumpy skin disease virus (neethling vaccine strain) expressing the rabies virus glycoprotein in cattle. Vaccine 20, 2693\u20132701 (2002).","journal-title":"Vaccine"},{"key":"441_CR88","first-page":"225","volume":"41","author":"A Mayr","year":"1978","unstructured":"Mayr, A. & Danner, K. Vaccination against pox diseases under immunosuppressive conditions. Dev. Biol. Stand. 41, 225\u2013234 (1978).","journal-title":"Dev. Biol. Stand."},{"key":"441_CR89","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","volume":"381","author":"PR Pittman","year":"2019","unstructured":"Pittman, P. R. et al. Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox. N. Engl. J. Med. 381, 1897\u20131908 (2019).","journal-title":"N. Engl. J. Med."},{"key":"441_CR90","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","volume":"188","author":"J Tartaglia","year":"1992","unstructured":"Tartaglia, J. et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217\u2013232 (1992).","journal-title":"Virology"},{"key":"441_CR91","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14760584.2019.1675518","volume":"18","author":"T Hanke","year":"2019","unstructured":"Hanke, T. Aiming for protective T cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials. Expert Rev. Vaccines 18, 1029\u20131041 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"441_CR92","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1164\/rccm.201108-1548OC","volume":"185","author":"TJ Scriba","year":"2012","unstructured":"Scriba, T. J. et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and\/or Mycobacterium tuberculosis-infected adults. Am. J. Respir. Crit. Care Med. 185, 769\u2013778 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"441_CR93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","volume":"220","author":"G Mutua","year":"2019","unstructured":"Mutua, G. et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J. Infect. Dis. 220, 57\u201367 (2019).","journal-title":"J. Infect. Dis."},{"key":"441_CR94","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/tbed.12444","volume":"64","author":"ESM Tuppurainen","year":"2017","unstructured":"Tuppurainen, E. S. M. et al. Review: Capripoxvirus diseases: current status and opportunities for control. Transbound. Emerg. Dis. 64, 729\u2013745 (2017).","journal-title":"Transbound. Emerg. Dis."},{"key":"441_CR95","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1099\/vir.0.19116-0","volume":"84","author":"K Aspden","year":"2003","unstructured":"Aspden, K., Passmore, J. A., Tiedt, F. & Williamson, A. L. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J. Gen. Virol. 84, 1985\u20131996 (2003).","journal-title":"J. Gen. Virol."},{"key":"441_CR96","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1743-422X-8-265","volume":"8","author":"YJ Shen","year":"2011","unstructured":"Shen, Y. J. et al. A novel candidate HIV vaccine vector based on the replication deficient capripoxvirus, lumpy skin disease virus (LSDV). Virol. J. 8, 265 (2011).","journal-title":"Virol. J."},{"key":"441_CR97","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1016\/j.vaccine.2006.11.066","volume":"25","author":"H Poulet","year":"2007","unstructured":"Poulet, H. et al. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 25, 5606\u20135612 (2007).","journal-title":"Vaccine"},{"key":"441_CR98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.copbio.2019.10.005","volume":"61","author":"S Murad","year":"2019","unstructured":"Murad, S. et al. Molecular pharming for low and middle income countries. Curr. Opin. Biotechnol. 61, 53\u201359 (2019).","journal-title":"Curr. Opin. Biotechnol."},{"key":"441_CR99","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/pbi.12412","volume":"13","author":"H Peyret","year":"2015","unstructured":"Peyret, H. & Lomonossoff, G. P. When plant virology met agrobacterium: the rise of the deconstructed clones. Plant. Biotechnol. J. 13, 1121\u20131135 (2015).","journal-title":"Plant. Biotechnol. J."},{"key":"441_CR100","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.14.150458","author":"E Margolin","year":"2020","unstructured":"Margolin, E. et al. Calreticulin co-expression supports high level production of a recombinant SARS-CoV-2 spike mimetic in Nicotiana benthamiana. bioRxiv https:\/\/doi.org\/10.1101\/2020.06.14.150458 (2020).","journal-title":"bioRxiv"},{"key":"441_CR101","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","volume":"8","author":"MA D\u2019Aoust","year":"2010","unstructured":"D\u2019Aoust, M. A. et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant. Biotechnol. J. 8, 607\u2013619 (2010).","journal-title":"Plant. Biotechnol. J."},{"key":"441_CR102","unstructured":"RT. DARPA\u2019s Blue Angel \u2014 Pentagon prepares millions of vaccines against future global flu. RT News https:\/\/www.rt.com\/usa\/future-vaccine-darpa-research-255\/ (2012)."},{"key":"441_CR103","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.24.20042937","author":"A Miller","year":"2020","unstructured":"Miller, A. et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.03.24.20042937 (2020).","journal-title":"medRxiv"},{"key":"441_CR104","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.07.20053272","author":"D Dayal","year":"2020","unstructured":"Dayal, D. & Gupta, S. Connecting BCG vaccination and COVID-19: additional data. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.04.07.20053272 (2020).","journal-title":"medRxiv"},{"key":"441_CR105","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.01.20049478","author":"A Shet","year":"2020","unstructured":"Shet, A., Ray, D., Malavige, N., Santosham, M. & Bar-Zeev, N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.04.01.20049478 (2020).","journal-title":"medRxiv"},{"key":"441_CR106","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.30.20048165","author":"G Sala","year":"2020","unstructured":"Sala, G. & Miyakawa, T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.03.30.20048165 (2020).","journal-title":"medRxiv"},{"key":"441_CR107","doi-asserted-by":"publisher","unstructured":"Abubakar, I. et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette\u2013Gu\u00e9rin vaccination against tuberculosis. Health Technol. Assess. https:\/\/doi.org\/10.3310\/hta17370 (2013).","DOI":"10.3310\/hta17370"},{"key":"441_CR108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","volume":"96","author":"GA Colditz","year":"1995","unstructured":"Colditz, G. A. et al. The efficacy of bacillus Calmette-Gu\u00e9rin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96, 29\u201335 (1995).","journal-title":"Pediatrics"},{"key":"441_CR109","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","volume":"25","author":"S Moorlag","year":"2019","unstructured":"Moorlag, S., Arts, R. J. W., van Crevel, R. & Netea, M. G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 25, 1473\u20131478 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"441_CR110","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3389\/fimmu.2019.02806","volume":"10","author":"C Covian","year":"2019","unstructured":"Covian, C. et al. BCG-induced cross-protection and development of trained immunity: implication for vaccine design. Front. Immunol. 10, 2806 (2019).","journal-title":"Front. Immunol."},{"key":"441_CR111","doi-asserted-by":"crossref","first-page":"e00439","DOI":"10.1128\/CVI.00439-16","volume":"24","author":"AG Loxton","year":"2017","unstructured":"Loxton, A. G. et al. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin. Vaccine Immunol. 24, e00439-16 (2017).","journal-title":"Clin. Vaccine Immunol."},{"key":"441_CR112","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.vaccine.2017.12.010","volume":"36","author":"T Cernuschi","year":"2018","unstructured":"Cernuschi, T., Malvolti, S., Nickels, E. & Friede, M. Bacillus Calmette-Gu\u00e9rin (BCG) vaccine: a global assessment of demand and supply balance. Vaccine 36, 498\u2013506 (2018).","journal-title":"Vaccine"},{"key":"441_CR113","unstructured":"WHO Africa. Outbreaks and emergencies bulletin. WHO https:\/\/www.afro.who.int\/health-topics\/disease-outbreaks\/outbreaks-and-other-emergencies-updates (2020)."},{"key":"441_CR114","unstructured":"UNAIDS. UNAIDS data 2019 https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2019-UNAIDS-data_en.pdf (2020)."},{"key":"441_CR115","doi-asserted-by":"crossref","first-page":"E314","DOI":"10.1016\/S2352-3018(20)30111-9","volume":"7","author":"JL Blanco","year":"2020","unstructured":"Blanco, J. L. et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV 7, E314\u2013E316 (2020).","journal-title":"Lancet HIV"},{"key":"441_CR116","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jmv.25732","volume":"92","author":"F Zhu","year":"2020","unstructured":"Zhu, F., Cao, Y., Xu, S. & Zhou, M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J. Med. Virol. 92, 529\u2013530 (2020).","journal-title":"J. Med. Virol."},{"key":"441_CR117","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1586\/17476348.2016.1157474","volume":"10","author":"DA Gonzalez Alvarez","year":"2016","unstructured":"Gonzalez Alvarez, D. A., Lopez Cortes, L. F. & Cordero, E. Impact of HIV on the severity of influenza. Expert Rev. Respir. Med. 10, 463\u2013472 (2016).","journal-title":"Expert Rev. Respir. Med."},{"key":"441_CR118","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3201\/eid1911.130546","volume":"19","author":"C Cohen","year":"2013","unstructured":"Cohen, C. et al. Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009\u20132011. Emerg. Infect. Dis. 19, 1766\u20131774 (2013).","journal-title":"Emerg. Infect. Dis."},{"key":"441_CR119","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiy310","volume":"218","author":"C von Mollendorf","year":"2018","unstructured":"von Mollendorf, C. et al. Influenza viral shedding in a prospective cohort of HIV-infected and uninfected children and adults in 2 provinces of South Africa, 2012\u20132014. J. Infect. Dis. 218, 1228\u20131237 (2018).","journal-title":"J. Infect. Dis."},{"key":"441_CR120","unstructured":"WHO. Global tuberculosis report 2019 https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329368\/9789241565714-eng.pdf (2020)."},{"key":"441_CR121","doi-asserted-by":"crossref","first-page":"ofz020","DOI":"10.1093\/ofid\/ofz020","volume":"6","author":"S Walaza","year":"2019","unstructured":"Walaza, S. et al. The impact of influenza and tuberculosis interaction on mortality among individuals aged \u226515 years hospitalized with severe respiratory illness in South Africa, 2010\u20132016. Open Forum Infect. Dis. 6, ofz020 (2019).","journal-title":"Open Forum Infect. Dis."},{"key":"441_CR122","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.02.20145185","author":"MA Davies","year":"2020","unstructured":"Davies, M. A. HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province, South Africa. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.07.02.20145185 (2020).","journal-title":"medRxiv"},{"key":"441_CR123","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4049\/jimmunol.1601560","volume":"198","author":"RF Tanko","year":"2017","unstructured":"Tanko, R. F. et al. Effect of antiretroviral therapy on the memory and activation profiles of B cells in HIV-infected African women. J. Immunol. 198, 1220\u20131228 (2017).","journal-title":"J. Immunol."},{"key":"441_CR124","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2018.06.001","volume":"195","author":"RF Tanko","year":"2018","unstructured":"Tanko, R. F. et al. Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression. Clin. Immunol. 195, 127\u2013138 (2018).","journal-title":"Clin. Immunol."},{"key":"441_CR125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/QCO.0b013e328334fec4","volume":"23","author":"AM Geretti","year":"2010","unstructured":"Geretti, A. M. & Doyle, T. Immunization for HIV-positive individuals. Curr. Opin. Infect. Dis. 23, 32\u201338 (2010).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"441_CR126","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1086\/429298","volume":"191","author":"A Malaspina","year":"2005","unstructured":"Malaspina, A. et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J. Infect. Dis. 191, 1442\u20131450 (2005).","journal-title":"J. Infect. Dis."},{"key":"441_CR127","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/apc.2014.0121","volume":"28","author":"NF Crum-Cianflone","year":"2014","unstructured":"Crum-Cianflone, N. F. & Wallace, M. R. Vaccination in HIV-infected adults. AIDS Patient Care STDS 28, 397\u2013410 (2014).","journal-title":"AIDS Patient Care STDS"},{"key":"441_CR128","unstructured":"WHO. At least 80 million children under one at risk of diseases such as diphtheria, measles and polio as COVID-19 disrupts routine vaccination efforts, warn Gavi, WHO and UNICEF. WHO https:\/\/www.who.int\/news-room\/detail\/22-05-2020-at-least-80-million-children-under-one-at-risk-of-diseases-such-as-diphtheria-measles-and-polio-as-covid-19-disrupts-routine-vaccination-efforts-warn-gavi-who-and-unicef (2020)."},{"key":"441_CR129","doi-asserted-by":"crossref","first-page":"e1132","DOI":"10.1016\/S2214-109X(20)30288-6","volume":"8","author":"A Hogan","year":"2020","unstructured":"Hogan, A. et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob. Health 8, e1132\u2013e1141 (2020).","journal-title":"Lancet Glob. Health"},{"key":"441_CR130","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.02.20051524","author":"M Triplett","year":"2020","unstructured":"Triplett, M. Evidence that higher temperatures are associated with lower incidence of COVID-19 in pandemic state, cumulative cases reported up to March 27, 2020. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.04.02.20051524 (2020).","journal-title":"medRxiv"},{"key":"441_CR131","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.3390\/ijerph17103493","volume":"17","author":"N Scafetta","year":"2020","unstructured":"Scafetta, N. Distribution of the SARS-CoV-2 pandemic and its monthly forecast based on seasonal climate patterns. Int. J. Environ. Res. Public Health 17, 3493 (2020).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"441_CR132","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.19.20039164","author":"J Alvarez-Ramirez Sr","year":"2020","unstructured":"Alvarez-Ramirez Sr, J. & Meraz, M. Role of meteorological temperature and relative humidity in the January\u2013February 2020 propagation of 2019-nCoV in Wuhan, China. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.03.19.20039164 (2020).","journal-title":"medRxiv"},{"key":"441_CR133","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","volume":"361","author":"JS Peiris","year":"2003","unstructured":"Peiris, J. S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319\u20131325 (2003).","journal-title":"Lancet"},{"key":"441_CR134","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41559-020-1212-8","volume":"4","author":"CJ Carlson","year":"2020","unstructured":"Carlson, C. J., Chipperfield, J. D., Benito, B. M., Telford, R. J. & O\u2019Hara, R. B. Species distribution models are inappropriate for COVID-19. Nat. Ecol. Evol. 4, 770\u2013771 (2020).","journal-title":"Nat. Ecol. Evol."},{"key":"441_CR135","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.08.20057281","author":"RS Harbert","year":"2020","unstructured":"Harbert, R. S., Cunningham, S. W. & Tessler, M. Spatial modeling cannot currently differentiate SARS-CoV-2 coronavirus and human distributions on the basis of climate in the United States. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.04.08.20057281 (2020).","journal-title":"medRxiv"},{"key":"441_CR136","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-012420-022445","author":"M Moriyama","year":"2020","unstructured":"Moriyama, M., Hugentobler, W. J. & Iwasaki, A. Seasonality of respiratory viral infections. Annu. Rev. Virol. https:\/\/doi.org\/10.1146\/annurev-virology-012420-022445 (2020).","journal-title":"Annu. Rev. Virol."},{"key":"441_CR137","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.es2013.18.38.20590","author":"N van Doremalen","year":"2013","unstructured":"van Doremalen, N., Bushmaker, T. & Munster, V. J. Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. Euro Surveill. https:\/\/doi.org\/10.2807\/1560-7917.es2013.18.38.20590 (2013).","journal-title":"Euro Surveill."},{"key":"441_CR138","first-page":"734690","volume":"2011","author":"KH Chan","year":"2011","unstructured":"Chan, K. H. et al. The effects of temperature and relative humidity on the viability of the SARS coronavirus. Adv. Virol. 2011, 734690 (2011).","journal-title":"Adv. Virol."},{"key":"441_CR139","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/35686514-b7a9-4f65-9663-7baefc0d63c0","volume":"8","author":"J Shaman","year":"2010","unstructured":"Shaman, J., Pitzer, V. E., Viboud, C., Grenfell, B. T. & Lipsitch, M. Absolute humidity and the seasonal onset of influenza in the continental United States. PLoS Biol. 8, e1000316 (2010).","journal-title":"PLoS Biol."},{"key":"441_CR140","volume":"10","author":"RE Baker","year":"2019","unstructured":"Baker, R. E. et al. Epidemic dynamics of respiratory syncytial virus in current and future climates. Nat. Commun. 10, 5512 (2019).","journal-title":"Nat. Commun."},{"key":"441_CR141","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/JCM.00636-10","volume":"48","author":"ER Gaunt","year":"2010","unstructured":"Gaunt, E. R., Hardie, A., Claas, E. C., Simmonds, P. & Templeton, K. E. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J. Clin. Microbiol. 48, 2940\u20132947 (2010).","journal-title":"J. Clin. Microbiol."},{"key":"441_CR142","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1473-3099(13)70204-4","volume":"13","author":"A Assiri","year":"2013","unstructured":"Assiri, A. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 13, 752\u2013761 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"441_CR143","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1126\/science.1092002","volume":"303","author":"SMEC Chinese","year":"2004","unstructured":"Chinese, S. M. E. C. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303, 1666\u20131669 (2004).","journal-title":"Science"},{"key":"441_CR144","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1098\/rstb.2004.1490","volume":"359","author":"RM Anderson","year":"2004","unstructured":"Anderson, R. M. et al. Epidemiology, transmission dynamics and control of SARS: the 2002\u20132003 epidemic. Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 1091\u20131105 (2004).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"441_CR145","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"441_CR146","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1073\/pnas.1708727114","volume":"114","author":"AC Walls","year":"2017","unstructured":"Walls, A. C. et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc. Natl Acad. Sci. USA 114, 11157\u201311162 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"441_CR147","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","volume":"428","author":"ZY Yang","year":"2004","unstructured":"Yang, Z. Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561\u2013564 (2004).","journal-title":"Nature"},{"key":"441_CR148","volume":"6","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 6, 7712 (2015).","journal-title":"Nat. Commun."},{"key":"441_CR149","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1099\/vir.0.82839-0","volume":"88","author":"L Yang","year":"2007","unstructured":"Yang, L. et al. Persistent memory CD4+ and CD8+ T cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. J. Gen. Virol. 88, 2740\u20132748 (2007).","journal-title":"J. Gen. Virol."},{"key":"441_CR150","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.micinf.2006.05.008","volume":"8","author":"H Peng","year":"2006","unstructured":"Peng, H. et al. Human memory T cell responses to SARS-CoV E protein. Microbes Infect. 8, 2424\u20132431 (2006).","journal-title":"Microbes Infect."},{"key":"441_CR151","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.virol.2006.03.036","volume":"351","author":"H Peng","year":"2006","unstructured":"Peng, H. et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 351, 466\u2013475 (2006).","journal-title":"Virology"},{"key":"441_CR152","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00281-016-0558-0","volume":"38","author":"AH Newton","year":"2016","unstructured":"Newton, A. H., Cardani, A. & Braciale, T. J. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin. Immunopathol. 38, 471\u2013482 (2016).","journal-title":"Semin. Immunopathol."},{"key":"441_CR153","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1128\/JVI.01505-14","volume":"88","author":"R Channappanavar","year":"2014","unstructured":"Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J. Virol. 88, 11034\u201311044 (2014).","journal-title":"J. Virol."},{"key":"441_CR154","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc070348","volume":"357","author":"WC Cao","year":"2007","unstructured":"Cao, W. C., Liu, W., Zhang, P. H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med. 357, 1162\u20131163 (2007).","journal-title":"N. Engl. J. Med."},{"key":"441_CR155","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1086\/500469","volume":"193","author":"W Liu","year":"2006","unstructured":"Liu, W. et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J. Infect. Dis. 193, 792\u2013795 (2006).","journal-title":"J. Infect. Dis."},{"key":"441_CR156","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1001\/jama.2020.2783","volume":"323","author":"L Lan","year":"2020","unstructured":"Lan, L. et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA 323, 1502\u20131503 (2020).","journal-title":"JAMA"},{"key":"441_CR157","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abc5343","volume":"369","author":"W Deng","year":"2020","unstructured":"Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369, 818\u2013823 (2020).","journal-title":"Science"},{"key":"441_CR158","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","volume":"7","author":"CT Tseng","year":"2012","unstructured":"Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).","journal-title":"PLoS ONE"},{"key":"441_CR159","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","volume":"12","author":"AS Agrawal","year":"2016","unstructured":"Agrawal, A. S. et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin. Immunother. 12, 2351\u20132356 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"441_CR160","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201\u201312215 (2011).","journal-title":"J. Virol."},{"key":"441_CR161","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02015-19","author":"Y Wan","year":"2020","unstructured":"Wan, Y. et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J. Virol. https:\/\/doi.org\/10.1128\/JVI.02015-19 (2020).","journal-title":"J. Virol."},{"key":"441_CR162","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202003.0138.v1","author":"DO Ricke","year":"2020","unstructured":"Ricke, D. O. & Malone, R. W. Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE). Preprints https:\/\/doi.org\/10.20944\/preprints202003.0138.v1 (2020).","journal-title":"Preprints"}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-020-00441-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-020-00441-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-020-00441-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:38:26Z","timestamp":1668688706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-020-00441-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":162,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1038\/s41579-020-00441-3","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"18 August 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}